Of the 300 patients in the PARCER trial, 93 faced grades ≥2 adverse events (3D-CRT = 59, IG-IMRT = 34). Patients in the 3D-CRT and IG-IMRT arms spent an average of 2.39 years and 1.96 years in ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--HyperLight, creator of the TFLN Chiplet™ platform, today announced the launch of its groundbreaking 110 GHz Low Vπ Intensity Modulator, featuring industry-standard ...
Role of induction chemotherapy with docetaxel+cisplatin+5-FU (DCF) followed by radiotherapy for patients with inoperable head and neck cancer to observe local control Target delineation, area coverage ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果